PMID- 30254636
OWN - NLM
STAT- MEDLINE
DCOM- 20190925
LR  - 20231103
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A 
      Bumpy Road.
PG  - 2052
LID - 10.3389/fimmu.2018.02052 [doi]
LID - 2052
AB  - Dendritic cells (DCs) are recognized as highly potent antigen-presenting cells 
      that are able to stimulate cytotoxic T lymphocyte (CTL) responses with antitumor 
      activity. Consequently, DCs have been explored as cellular vaccines in cancer 
      immunotherapy. To that end, DCs are modified with tumor antigens to enable 
      presentation of antigen-derived peptides to CTLs. In this review we discuss the 
      use of viral vectors for in situ modification of DCs, focusing on their clinical 
      applications as anticancer vaccines. Among the viral vectors discussed are those 
      derived from viruses belonging to the families of the Poxviridae, Adenoviridae, 
      Retroviridae, Togaviridae, Paramyxoviridae, and Rhabdoviridae. We will further 
      shed light on how the combination of viral vector-based vaccination with T-cell 
      supporting strategies will bring this strategy to the next level.
FAU - Goyvaerts, Cleo
AU  - Goyvaerts C
AD  - Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, 
      Vrije Universiteit Brussel, Jette, Belgium.
FAU - Breckpot, Karine
AU  - Breckpot K
AD  - Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, 
      Vrije Universiteit Brussel, Jette, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180911
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - *Cancer Vaccines/immunology/therapeutic use
MH  - Cell Engineering/*methods
MH  - Dendritic Cells/*immunology/pathology
MH  - *Genetic Vectors
MH  - Humans
MH  - Immunotherapy/*methods
MH  - *Neoplasms/genetics/immunology/pathology/therapy
MH  - T-Lymphocytes, Cytotoxic/immunology/pathology
MH  - *Viruses
PMC - PMC6141723
OTO - NOTNLM
OT  - T cell
OT  - cancer
OT  - dendritic cell
OT  - immunotherapy
OT  - preclinical and clinical
OT  - viral vaccine
EDAT- 2018/09/27 06:00
MHDA- 2019/09/26 06:00
PMCR- 2018/01/01
CRDT- 2018/09/27 06:00
PHST- 2018/06/28 00:00 [received]
PHST- 2018/08/20 00:00 [accepted]
PHST- 2018/09/27 06:00 [entrez]
PHST- 2018/09/27 06:00 [pubmed]
PHST- 2019/09/26 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.02052 [doi]
PST - epublish
SO  - Front Immunol. 2018 Sep 11;9:2052. doi: 10.3389/fimmu.2018.02052. eCollection 
      2018.